Science and Research

A Multicentre, Double-blind, Randomized, Parallel Group, Placebo Controlled, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (Destination)

To evaluate the long-term safety and tolerability of tezepelumab in severe asthma subjects

Study details
Study-ID: 2018-002501-53
DZL Disease Area: AA
Study Type: Interventional
DZL Role: DZL recruiting center
Funding: Externally - industry
DZL Participating Sites: BREATH
Start Date: 06.01.2020
Completion Date: 01.09.2022
Status: Closed
Link to Study


chevron-down